US Medical Innovations announced the United States Patent Office (USPO) has issued USPI patent No. 10,023,858 B2, further expanding its intellectual patent property portfolio for the application of delivering Cold Atmospheric Plasma (CAP) technology to selectively target cancer cells.
Researchers at the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), Takoma Park, Md., have successfully demonstrated the use of CAP for elevating TRAIL-R1 (Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 1 expression in cancer cells to induce apoptosis.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“Breast cancer represents 23% of total cancer cases and 14% of the deaths related to cancers. These cancers are identified by subtypes and the presence or absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER 2). Patients with HER2 positive breast tumors have the second poorest survival among breast cancer subtypes,” Dr. Canady (CEO of JCRI-ABTS and USMI) said.
Utilizing USMI’s patented electrosurgical plasma system, CAP is delivered through the Canady Helios Plasma Scalpel, in conjunction with this patented process for elevating a TRAIL-R1 expression in cancer cells, to induce apoptosis. The method entails the steps involved in using electrical energy with a specific voltage, frequency and power from the Cold Plasma Generator (recently issued patent no. 9,999,452) and applying the cold plasma to the surgical margins to target cancer cells. The invention identifies the involvement of a new receptor in plasma medicine, a Tumor Necrosis Factor (TNF) inducing ligand (TRAIL). The TRAIL receptor 1 (TRAIL R-1) activates apoptosis through the death receptors DR4 and DR5. In breast cancer epithelial cells, TRAIL R-1 expression was elevated when treated with CAP while normal breast cells were unaffected.